Tharimmune Inc (THAR)

May 12, 2025

Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 12, 2025

May 12, 2025

Tharimmune, Inc. SEC 10-Q Report - TradingView

May 12, 2025

May 10, 2025

Tharimmune appoints new executive chairman By Investing.com - Investing.com India

May 10, 2025

May 10, 2025

Tharimmune appoints new executive chairman - Investing.com Australia

May 10, 2025

May 09, 2025

Tharimmune IncAppoints Vincent Lopriore As Executive ChairmanSEC Filing - marketscreener.com

May 09, 2025

May 06, 2025

Tharimmune (THAR) Reports Promising Phase 1 Results for TH104 Bu - GuruFocus

May 06, 2025

May 06, 2025

Tharimmune (THAR) Advances TH104 as Key Medical Countermeasure | - GuruFocus

May 06, 2025

May 06, 2025

Tharimmune advances opioid prophylaxis drug TH104 - Investing.com

May 06, 2025

May 06, 2025

Tharimmune advances opioid prophylaxis drug TH104 By Investing.com - Investing.com South Africa

May 06, 2025

May 06, 2025

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback - Corsicana Daily Sun

May 06, 2025

May 06, 2025

Tharimmune's New Drug Breakthrough: FDA Fast-Tracks Military Protection Against Weaponized Fentanyl - Stock Titan

May 06, 2025

May 05, 2025

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences - Chronicle-Tribune

May 05, 2025

May 03, 2025

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors - Bluefield Daily Telegraph

May 03, 2025

May 01, 2025

Stocks of Tharimmune Inc (THAR) are poised to climb above their peers - Sete News

May 01, 2025

May 01, 2025

Breakthrough Drug TH104 Clinical Data Selected for Two Premier Medical Conferences DDW and EASL - Stock Titan

May 01, 2025

Apr 30, 2025

Tharimmune Appoints Clay Kahler And Gary Stetz To Board - citybiz

Apr 30, 2025

Apr 30, 2025

Tharimmune (THAR) Expands Board with New Appointments | THAR Sto - GuruFocus

Apr 30, 2025

Apr 30, 2025

Tharimmune expands board with two new directors By Investing.com - Investing.com India

Apr 30, 2025

Apr 30, 2025

Tharimmune expands board with two new directors - Investing.com

Apr 30, 2025

Apr 30, 2025

Tharimmune Adds $500M Success Story Entrepreneur and Financial Expert to Board Leadership - Stock Titan

Apr 30, 2025

Apr 29, 2025

Tharimmune Inc’s latest rating changes from various analysts - knoxdaily.com

Apr 29, 2025

Apr 29, 2025

Tharimmune Inc (THAR) Stock: Uncovering 52-Week Market Trends - investchronicle.com

Apr 29, 2025

Apr 29, 2025

These Numbers Show Just How Powerful Tharimmune Inc (NASDAQ: THAR) Stock ‎Is - Stocksregister

Apr 29, 2025

Apr 29, 2025

Tharimmune expands board, appoints new directors By Investing.com - Investing.com Nigeria

Apr 29, 2025

Apr 29, 2025

Tharimmune expands board, appoints new directors - Investing.com

Apr 29, 2025

Apr 28, 2025

FDA Nods to Tharimmune’s Countermeasure for Opioid Threats By Investing.com - Investing.com South Africa

Apr 28, 2025

Apr 28, 2025

FDA Nods to Tharimmune’s Countermeasure for Opioid Threats - Investing.com Australia

Apr 28, 2025

Apr 28, 2025

Now Is The Time To Build A Position In Tharimmune Inc (NASDAQ:THAR) - Marketing Sentinel

Apr 28, 2025

Apr 28, 2025

Observations on the Tharimmune Inc (NASDAQ:THAR) Growth Curve - uspostnews.com

Apr 28, 2025

Apr 28, 2025

Tharimmune (THAR) Advances TH104 with FDA Feedback on New Drug A - GuruFocus

Apr 28, 2025

Apr 28, 2025

Tharimmune (THAR) Advances TH104 with FDA Feedback on New Drug Application | THAR Stock News - GuruFocus

Apr 28, 2025

Apr 28, 2025

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - The Joplin Globe

Apr 28, 2025

Apr 28, 2025

FDA Clears Path for Tharimmune's Military-Grade Fentanyl Defense Drug: No New Trials Needed - Stock Titan

Apr 28, 2025

Apr 25, 2025

Tharimmune announces board retirements ahead of annual meeting - Investing.com

Apr 25, 2025

Apr 25, 2025

Tharimmune announces board retirements ahead of annual meeting By Investing.com - Investing.com South Africa

Apr 25, 2025

Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025

Apr 15, 2025

Tharimmune (THAR) Expands Board with New Appointment | THAR Stoc - GuruFocus

Apr 15, 2025

Apr 15, 2025

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors - Chronicle-Tribune

Apr 15, 2025

Apr 15, 2025

Healthcare Investment Expert Managing $150M Portfolio Strengthens Tharimmune's Strategic Leadership - Stock Titan

Apr 15, 2025

Apr 08, 2025

Tharimmune reports data on new biparatopic biologics - BioWorld MedTech

Apr 08, 2025

Apr 07, 2025

THAR stock touches 52-week low at $1.12 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 07, 2025

THAR stock touches 52-week low at $1.12 amid sharp annual decline - Investing.com Australia

Apr 07, 2025

Apr 07, 2025

Tharimmune Reports Preclinical Data for Dual-Target Biologics - MarketScreener

Apr 07, 2025

Apr 07, 2025

Tharimmune Announces Positive Data With Novel Biparatopic PD-1/VEGF & Multispecific HER2/HER3 Biologics Leveraging Proprietary Epiclick(TM) Technology - MarketScreener

Apr 07, 2025

Apr 07, 2025

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology - Weatherford Democrat

Apr 07, 2025

Apr 07, 2025

Breakthrough Cancer Drug Shows Superior Design: Tharimmune's Dual-Target Biologic Outperforms Competition - Stock Titan

Apr 07, 2025

Apr 05, 2025

Tharimmune receives Nasdaq non-compliance notice By Investing.com - Investing.com India

Apr 05, 2025

Apr 05, 2025

Tharimmune receives Nasdaq non-compliance notice - Investing.com Australia

Apr 05, 2025